PMID- 8726941
OWN - NLM
STAT- MEDLINE
DCOM- 19961122
LR  - 20190821
IS  - 0903-1936 (Print)
IS  - 0903-1936 (Linking)
VI  - 9
IP  - 4
DP  - 1996 Apr
TI  - In vitro modulation of induced neutrophil activation by different surfactant 
      preparations.
PG  - 752-7
AB  - Endotracheal surfactant administration has gained an important role in the 
      treatment of respiratory failure. Polymorphonuclear neutrophil granulocyte (PMN) 
      activation mediated by chemoattractants, such as interleukin-8 (IL-8), 
      neutrophil-activating peptide-2 (NAP-2) and formylated bacterial oligopeptides, 
      has been found to be involved in the pathophysiology of acute respiratory 
      failure. We investigated potential modulating effects of commercial surfactant 
      preparations (Exosurf, Alveofact, Curosurf and Survanta) on spontaneous and 
      chemoattractant-induced PMN function. Isolated cytochalasin B (CytB)-treated PMNs 
      from healthy adults were incubated with increasing concentrations of surfactant. 
      The response of the cells was measured in terms of elastase release from the 
      lysosomes within 30 min. The PMNs showed no direct activation by any of the 
      surfactants tested. However, when cells were stimulated with suboptimal dosages 
      of chemokines, such as IL-8 (2 nM) or NAP-2 (100 nM), or 
      formyl-methionyl-leucyl-phenylalanine (fMLP) (50 nM), and co-incubated with 
      increasing concentrations of surfactant (0.05-8 mg.mL-1) the release of elastase 
      was markedly modulated depending on the surfactant preparation used. Whilst 
      Exosurf and Alveofact showed only modest effects on the elastase release induced 
      by all three mediators, Curosurf and Survanta markedly inhibited the cellular 
      response in a dose-dependent manner. At concentrations above 1 mg.mL-1, Curosurf 
      and Survanta decreased the IL-8-, NAP-2- and fMLP-induced elastase release by 83, 
      67 and 90%, and by 82, 75 and 80%, respectively. In conclusion, exogenous 
      surfactant may modulate the inflammatory response of the airways by affecting the 
      chemoattractant-induced polymorphonuclear neutrophil activation. Surfactant 
      preparations with inhibiting properties on neutrophil activation may participate 
      in the prevention of neutrophil-induced lung damage.
FAU - Tegtmeyer, F K
AU  - Tegtmeyer FK
AD  - Children's Hospital, Park Schonfeld, Kassel, FRG.
FAU - Gortner, L
AU  - Gortner L
FAU - Ludwig, A
AU  - Ludwig A
FAU - Brandt, E
AU  - Brandt E
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur Respir J
JT  - The European respiratory journal
JID - 8803460
RN  - 0 (Interleukin-8)
RN  - 0 (PPBP protein, human)
RN  - 0 (Peptides)
RN  - 0 (Surface-Active Agents)
RN  - 0 (beta-Thromboglobulin)
RN  - 59880-97-6 (N-Formylmethionine Leucyl-Phenylalanine)
RN  - 69344-77-0 (connective tissue-activating peptide)
RN  - EC 3.4.21.37 (Leukocyte Elastase)
SB  - IM
MH  - Adult
MH  - Cells, Cultured
MH  - Humans
MH  - Interleukin-8/immunology
MH  - Leukocyte Elastase/metabolism
MH  - Lysosomes/enzymology
MH  - N-Formylmethionine Leucyl-Phenylalanine/immunology
MH  - Neutrophil Activation/*drug effects
MH  - Neutrophils/chemistry/enzymology
MH  - Peptides/immunology
MH  - Surface-Active Agents/*pharmacology
MH  - beta-Thromboglobulin
EDAT- 1996/04/01 00:00
MHDA- 1996/04/01 00:01
CRDT- 1996/04/01 00:00
PHST- 1996/04/01 00:00 [pubmed]
PHST- 1996/04/01 00:01 [medline]
PHST- 1996/04/01 00:00 [entrez]
AID - 10.1183/09031936.96.09040752 [doi]
PST - ppublish
SO  - Eur Respir J. 1996 Apr;9(4):752-7. doi: 10.1183/09031936.96.09040752.